Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Zevra Therapeutics Resubmits Its New Drug Application For Arimoclomol For Niemann-pick Disease Type C To FDA. Zevra Expects The Application To Be Classified As A Class II Submission Which Would Be Subject To A Review Period By FDA Within Six Months

Author: Benzinga Newsdesk | December 27, 2023 08:33am

Posted In: ZVRA